natgillin/translations-raw huggingface dataset:
In the second study, 89% (155 out of 175) of patients on Nulojix and 85% (157 out 184) of those on cyclosporine A survived with their kidneys intact.
V drugi študiji je 89 % (155 od 175) bolnikov, ki so prejemali zdravilo Nulojix, in 85 % (157 od 184) bolnikov, ki so prejemali ciklosporin A, preživelo brez sprememb na ledvici.
Nulojix was shown to improve patient and organ survival following kidney transplantation.
Za zdravilo Nulojix so dokazali, da izboljšuje preživetje bolnikov in organa po presaditvi ledvice.
What is the risk associated with Nulojix?
Kakšna tveganja so povezana z zdravilom Nulojix?
Some patients were given intensive Nulojix treatment which involved a longer initial phase of six months.
Nekatere bolnike so zdravili z intenzivno terapijo z zdravilom Nulojix, pri kateri je bilo začetno obdobje daljše in je trajalo šest mesecev.
This is because patients treated with Nulojix who have had no previous exposure to the virus are at higher risk of getting a type of cancer known as post-transplant lymphoproliferative disorder.
Pri bolnikih, ki se zdravijo z zdravilom Nulojix in ki predhodno niso bili izpostavljeni temu virusu, namreč obstaja večje tveganje za razvoj raka, imenovanega potransplantacijska limfoproliferativna bolezen.
All patients were also treated with corticosteroids, mycophenolic acid, and basiliximab (an interleukin-2 receptor antagonist) during the first week after transplantation.
Vse bolnike so prvi teden po presaditvi zdravili tudi s kortikosteroidi, mikofenolno kislino in baziliksimabom (antagonistom receptorja za interlevkin-2).
The proportion of patients who had an episode of organ rejection within one year was 17% for Nulojix and 7% for cyclosporine A.
Delež bolnikov, pri katerih je v enem letu po presaditvi prišlo do zavrnitve organa, je bil pri zdravilu Nulojix 17 %, pri ciklosporinu A pa 7 %.
For the full list of all side effects reported with Nulojix, see the package leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Nulojix, glejte navodilo za uporabo.
Nulojix is used in adults to prevent the body from rejecting a transplanted kidney.
Zdravilo Nulojix se uporablja pri odraslih za preprečevanje zavrnitve ledvice po presaditvi.
The active substance in Nulojix, belatacept, is an immunosuppressive medicine.
Zdravilna učinkovina zdravila Nulojix, belatacept, je zdravilo za zaviranje imunske odzivnosti.
The proportion of patients with impaired kidney function was 77% in patients on Nulojix and 85% in patients on cyclosporine A. Around 18% of patients on Nulojix had an episode of organ rejection within one year compared with 14% of patients on cyclosporine A.
Delež bolnikov z okvaro ledvice je bil 77 % pri bolnikih, ki so prejemali zdravilo Nujolix, in 85 % pri tistih, ki so prejemali ciklosporin A. Pri okoli 18 % bolnikov, ki so jemali Nulojix, je v enem letu po presaditvi prišlo do epizode zavrnitve organa v primerjavi s 14 % bolnikov, ki so jemali ciklosporin A.
Nulojix is a powder that is made up into a solution for infusion (drip into a vein).
Zdravilo Nulojix je prašek za pripravo raztopine za infundiranje (kapalne infuzije v veno).
Why has Nulojix been approved?
Zakaj je bilo zdravilo Nulojix odobreno?
An interleukin-2 receptor antagonist medicine should also be used with Nulojix during the first week after the kidney transplant.
V prvem tednu po presaditvi ledvice je treba z zdravilom Nulojix uporabljati še antagonist receptorja za interlevkin-2.
In the first study, 97% of patients receiving Nulojix treatment survived with their kidneys intact (218 out of 226) compared with 93% of patients receiving cyclosporine A (206 out 221).
V prvi študiji je 97 % (218 od 226) bolnikov, ki so prejemali zdravilo Nulojix, preživelo brez sprememb na ledvici , v primerjavi s 93 % (206 od 221) bolnikov, ki so prejemali ciklosporin A. Okoli 54 % bolnikov, ki so prejemali zdravilo Nulojix, in 78 % tistih, ki so prejemali ciklosporin A, je imelo okvaro ledvic.
How has Nulojix been studied?
Kako je bilo zdravilo Nulojix raziskano?
What is Nulojix used for?
Za kaj se zdravilo Nulojix uporablja?
How does Nulojix work?
Kako zdravilo Nulojix deluje?
How is Nulojix used?
Kako se zdravilo Nulojix uporablja?
What is Nulojix?
Kaj je zdravilo Nulojix?
After the initial doses, it is usually given once every 8 weeks.
Po začetnih odmerkih se običajno daje enkrat na vsakih osem tednov.
This means that it is highly similar to another biological medicine (the ‘reference medicine') that is already authorised in the EU.
To pomeni, da je zelo podobno drugemu biološkemu zdravilu („referenčnemu zdravilu“), ki je že odobreno v EU.
Further information on Zessly can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Več informacij o zdravilu Zessly je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
What measures are being taken to ensure the safe and effective use of Zessly?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Zessly?
A similar proportion of patients achieved a 20% reduction with the two medicines (around 61.1% with Zessly and 63.5% with Remicade).
Do 20-odstotnega zmanjšanja je prišlo pri podobnem deležu bolnikov pri obeh zdravilih (približno 61,1 % z zdravilom Zessly in 63,5 % z zdravilom Remicade).
For Crohn's disease and ulcerative colitis, it is also used in children from 6 years of age.
Pri Crohnovi bolezni in ulceroznem kolitisu se uporablja tudi pri otrocih, starejših od šest let.
An overview of Zessly and why it is authorised in the EU
Pregled zdravila Zessly in zakaj je odobreno v EU
What benefits of Zessly have been shown in studies?
Kakšne koristi zdravila Zessly so se pokazale v študijah?
What is Zessly and what is it used for?
Kaj je zdravilo Zessly in za kaj se uporablja?
Why is Zessly authorised in the EU?
Zakaj je bilo zdravilo Zessly odobreno v EU?
Zessly is used mainly in adults, usually when other medicines or treatments have failed or cannot be used.
Zdravilo Zessly se uporablja večinoma pri odraslih, običajno takrat, ko druga zdravila ali načini zdravljenja niso bili uspešni oziroma jih ni mogoče uporabiti.
What are the risks associated with Zessly?
Kakšna tveganja so povezana z zdravilom Zessly?
Zessly is an anti-inflammatory medicine for treating the following diseases:
Zessly je protivnetno zdravilo za zdravljenje naslednjih bolezni:
After each infusion, the patient should be monitored for 1 to 2 hours in case they have an allergic reaction, such as swelling of the mouth, face and throat, skin rash, and difficulty breathing.
Po vsaki infuziji je treba bolnika spremljati eno do dve uri, saj se lahko pri njem pojavi alergijska reakcija, kot je otekanje ust, obraza in grla, kožni izpuščaj in težave z dihanjem.
For some conditions, Zessly is also used in combination with another medicine, methotrexate.
Pri nekaterih boleznih se zdravilo Zessly uporablja tudi v kombinaciji z drugim zdravilom, metotreksatom.
Zessly must also not be used in patients with tuberculosis, other severe infections, or moderate or severe heart failure (an inability of the heart to pump enough blood around the body).
Ne sme se uporabljati pri bolnikih s tuberkulozo, drugimi hudimi okužbami ali zmernim do hudim srčnim popuščanjem (nezmožnostjo srca, da črpa dovolj krvi po telesu).
By attaching to TNF-α, infliximab blocks its activity and thereby reduces inflammation and other symptoms of the diseases.
Infliksimab z vezavo na TNF-α zavre njegovo delovanje ter tako zmanjša vnetja in druge simptome bolezni.
Side effects reported with Zessly are carefully evaluated and any necessary action taken to protect patients.
Neželeni učinki, o katerih so poročali pri zdravilu Zessly, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
To reduce the risk of infusion reactions, patients may be given other medicines before or during treatment with Zessly or the infusion may be slowed down.
Za zmanjšanje tveganja za pojav infuzijskih reakcij lahko bolniki pred zdravljenjem z zdravilom Zessly ali med njim prejemajo druga zdravila ali pa se hitrost infundiranja upočasni.
The European Medicines Agency decided that, in accordance with EU requirements for biosimilar medicines, Zessly has been shown overall to have a comparable quality, safety and effectiveness to Remicade.
Evropska agencija za zdravila je zaključila, da je bilo v skladu z zahtevami EU glede podobnih bioloških zdravil dokazano, da je zdravilo Zessly po kakovosti, varnosti in učinkovitosti primerljivo zdravilu Remicade.
The most common side effects with Zessly (seen in more than 1 patient in 10) are viral infections (such as flu and cold sores), headache, upper respiratory tract infection (nose and throat infection), sinusitis (inflammation of the sinuses), nausea (feeling sick), abdominal pain (stomach ache), infusionrelated reactions and pain.
Najpogostejši neželeni učinki zdravila Zessly (opaženi pri več kot 1 bolniku od 10) so virusne okužbe (na primer gripa ali herpes), glavobol, okužbe zgornjih dihal (okužbe nosu in žrela), sinusitis (vnetje sinusov), navzeja (slabost), bolečine v trebuhu, reakcije, povezane z infuzijo, in bolečine.
As for all medicines, data on the use of Zessly are continuously monitored.
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Zessly stalno spremljajo.
The study looked at the proportion of patients who achieved at least a 20% reduction in ACR scores (a measure of painful, swollen joints and other symptoms) after 14 weeks of treatment.
V študiji so proučevali delež bolnikov, pri katerih je po 14 tednih zdravljenja prišlo do najmanj 20-odstotnega zmanjšanja rezultata ACR (merilo za boleče, otekle sklepe in druge simptome).
In addition, Zessly was as effective as Remicade in a study of 650 rheumatoid arthritis patients whose previous treatment with methotrexate alone had not worked well enough.
Poleg tega je bilo zdravilo Zessly v študiji pri 650 bolnikih z revmatoidnim artritisom, pri katerih predhodno zdravljenje s samim metotreksatom ni bilo dovolj uspešno, enako učinkovito kot zdravilo Remicade.
Zessly is given as an infusion (drip) into a vein over 2 hours.
Zdravilo Zessly se daje kot (kapalna) infuzija v veno, ki traja dve uri.
Other information about Zessly
Druge informacije o zdravilu Zessly
The active substance in Zessly, infliximab, is a monoclonal antibody (a type of protein) that attaches to a substance in the body called tumour necrosis factor alpha (TNF-α).
Učinkovina v zdravilu Zessly, infliksimab, je monoklonsko protitelo (vrsta beljakovine), ki se veže na snov, imenovano tumorje nekrotizirajoči faktor alfa (TNF-α).
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Zessly have also been included in the summary of product characteristics and the package leaflet.
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Zessly upoštevati zdravstveni delavci in bolniki, so vključeni tudi v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
In particular, information will be provided for doctors who intend to prescribe the medicine to children with Crohn's disease or ulcerative colitis, to explain that these patients may be at an increased risk of developing infections and to remind of the importance of keeping vaccinations up to date.
Zdravniki, ki nameravajo to zdravilo predpisovati otrokom s Crohnovo boleznijo ali ulceroznim kolitisom, bodo prejeli še posebne informacije, v katerih bo pojasnjeno, da pri teh bolnikih obstaja povečano tveganje za okužbe, opozorjeni pa bodo tudi na pomembnost rednega cepljenja.
The company that markets Zessly will provide an alert card for patients and educational material for prescribers, summarising the safety information about the medicine.
Družba, ki trži zdravilo Zessly, bo priskrbela opozorilno kartico za bolnike in izobraževalno gradivo za zdravnike, ki bodo to zdravilo predpisovali, v katerih bodo navedene informacije o varnosti zdravila.
Because Zessly is a biosimilar medicine, the studies on effectiveness and safety carried out with Remicade do not all need to be repeated for Zessly.
Zdravilo Zessly je podobno biološko zdravilo, zato vseh študij o učinkovitosti in varnosti, izvedenih z zdravilom Remicade, pri zdravilu Zessly ni treba ponavljati.
Zessly can only be obtained with a prescription and treatment should be started and supervised by a specialist doctor who has experience in the diagnosis and treatment of the diseases that Zessly is used to treat.
Predpisovanje in izdaja zdravila Zessly je le na recept, zdravljenje z njim pa lahko uvede in nadzoruje le zdravnik specialist, ki ima izkušnje z diagnosticiranjem in zdravljenjem bolezni, za katere se zdravilo Zessly uporablja.
This substance is involved in causing inflammation and is found at high levels in patients with the diseases that Zessly is used to treat.
Ta snov sodeluje pri nastanku vnetij in je v visokih koncentracijah prisotna pri bolnikih z boleznimi, za zdravljenje katerih se uporablja zdravilo Zessly.
Zessly must not be used in patients who are hypersensitive (allergic) to infliximab, mouse proteins or any of the other ingredients of Zessly.
Zdravila Zessly ne smejo jemati bolniki, ki so preobčutljivi za (alergični na) infliksimab, mišje beljakovine ali na katero koli drugo sestavino zdravila.
For more information about using Zessly, see the package leaflet or contact your doctor or pharmacist.
Za več informacij glede uporabe zdravila Zessly glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
• psoriasis (red, scaly patches on the skin)
• psoriaze (rdečih, luskastih zaplat na koži);
• Crohn's disease (disease causing inflammation of the gut)
• Crohnove bolezni (bolezni, ki povzroča vnetje črevesa);
The dose of Zessly and how often it is given depends on the patient's body weight and the condition being treated.
Odmerek zdravila Zessly in pogostnost dajanja sta odvisna od bolnikove telesne mase in zdravljene bolezni.
• ankylosing spondylitis (inflammation of spine causing back pain)
• ankilozirajočega spondilitisa (vnetja hrbtenice, ki povzroča bolečine v hrbtu);
Laboratory studies comparing Zessly with Remicade have shown that the active substance in Zessly is highly similar to that in Remicade in terms of structure, purity and biological activity.
Laboratorijske študije, v katerih so zdravilo Zessly primerjali z zdravilom Remicade, so pokazale, da je učinkovina v zdravilu Zessly po zgradbi, čistosti in biološkem delovanju zelo podobna učinkovini v zdravilu Remicade.
• psoriatic arthritis (psoriasis with inflammation of the joints).
• psoriatičnega artritisa (psoriaze z vnetjem sklepov).
Studies have also shown that giving Zessly produces similar levels of the active substance in the body to giving Remicade.
Študije so pokazale tudi, da zdravilo Zessly vzpostavi podobne ravni učinkovine v telesu kot zdravilo Remicade.
How is Zessly used?
Kako se zdravilo Zessly uporablja?
• ulcerative colitis (inflammation and ulcers in the lining of the gut)
• ulceroznega kolitisa (vnetja in razjed v črevesni sluznici);
Therefore, the Agency's view was that, as for Remicade, the benefit of Zessly outweighs the identified risk and it can be authorised.
Menila je, da koristi zdravila Zessly enako kot pri zdravilu Remicade odtehtajo znana tveganja in da se zdravilo lahko odobri.
The reference medicine for Zessly is Remicade.
Referenčno zdravilo za zdravilo Zessly je zdravilo Remicade.
Zessly is a ‘biosimilar medicine'.
Zdravilo Zessly je „podobno biološko zdravilo“.
For the full list of side effects of Zessly, see the package leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Zessly, glejte navodilo za uporabo.
• rheumatoid arthritis (disease causing inflammation of the joints)
• revmatoidnega artritisa (bolezni, ki povzroča vnetje sklepov);
How does Zessly work?
Kako zdravilo Zessly deluje?
Bratislava, Slovakia.
Bratislava, Slovaška.
152 32 Halandri, Athens
152 32 Halandri, Atene
170 09 Sverige (SWE)
170 09 Sverige (SWE) Švedska
Meda AS Solvang 8
Danska Meda AS Solvang 8
Bruninieku 5, Riga, LV1001, Latvia
Bruninieku 5, Riga, LV1001, Latvija
A-1140 Wien
A-1140 Dunaj
A. Goštauto g. 40A LT-01112 Vilnius, Lithuania
A. Goštauto g. 40A LT-01112 Vilnius, Litva
Slovak Republic GlaxoSmithKline Slovakia sro., Galvaniho7/A, 82104
Slovaška GlaxoSmithKline Slovakia sro., Galvaniho7/A, 82104
28760 Tres Cantos (Madrid).
28760 Tres Cantos
GlaxoSmithKline 100, route de Versailles78163 Marly-le-Roi Cedex
Francija Laboratoire GlaxoSmithKline 100, route de Versailles78163 Marly-le-Roi Cedex
GlaxoSmithKline Pharma GmbH, Albert SchweitzerGasse 6,
Avstrija GlaxoSmithKline Pharma GmbH, Albert SchweitzerGasse 6,
GlaxoSmithKline Latvia SIA
Latvija GlaxoSmithKline Latvia SIA
GlaxoSmithKline Export Ltd
Poljska GlaxoSmithKline Export Ltd
GSK d.o.o., Ljubljana Knezov štradon 90 SI-1000 Ljubljana Slovenija
Slovenija GSK d.o.o., Ljubljana Knezov štradon 90
Bial - Portela & Cª, S.A À Av. da Siderurgia Nacional - 4745-457 S. Mamede do Coronado Portugal
Bial - Portela & Cª, S.A À Av. da Siderurgia Nacional - 4745-457 S. Mamede do Coronado Portugalska
Glaxo Smith Kline B.V. Huis ter Heideweg 62 3705 LZ ZEIST THE NETHERLANDS
Huis ter Heideweg 62 3705 LZ ZEIST NIZOZEMSKA
À Av. da Siderurgia Nacional - 4745-457 S. Mamede do Coronado Portugal
À Av. da Siderurgia Nacional - 4745-457 S. Mamede do Coronado Portugalska
1000mg : 200mg/ 20.9ml or 120ml
1000 mg : 200 mg/ 20,9 ml ali 120 ml
GlaxoSmithKline ehf.
Islandija GlaxoSmithKline ehf.
Laboratórios BIAL À Av. da Siderurgia Nacional - 4745-457 S. Mamede do Coronado Portugal
Laboratórios BIAL À Av. da Siderurgia Nacional - 4745-457 S. Mamede do Coronado Portugalska
Augmentin Intravenous 600mg & 1.2gm
Augmentin Intravenous 600 mg & 1,2 mg
Waterford Road Clonmel
Clonmel Healthcare Limited Waterford Road Clonmel
SmithKline Beecham plc.
Estonija SmithKline Beecham plc.
Dispersible tablets Oral use
Disperzibilna tableta Peroralna uporaba
Augmentin 500/125mg FilmCoated Tablets
Augmentin 500/125 mg Film-Coated Tablets
P.T.M.- C/Severo Ochoa, 2 28760 Tres Cantos (Madrid).
Laboratorios Beecham, S.A. P.T.M.- C/Severo Ochoa, 2 28760 Tres Cantos (Madrid).
GlaxoSmithKline GmbH & Co. KG
Nemčija GlaxoSmithKline GmbH & Co.
Intravenous 500mg/100mg Powder for Solution for Injection or Infusion
500 mg/100 mg Powder for Solution for Injection or Infusion
Box 906
Švedska Meda AB Box 906
GlaxoSmithKline EOOD Ivan Vasov Complex Dimitar Manov street,
Bolgarija GlaxoSmithKline EOOD Ivan Vasov Complex Dimitar Manov street, bl.10, 1408 Sofija, Bolgarija
Clavamox 312,5 mg/5 mlTrockensaft
Clavamox 312,5 mg/5 ml - Trockensaft
500mg : 50mg/ vial
500 mg : 50 mg/ vialo
125/31.25mg/ 5mlOral suspension Oral use
125/31,25 mg/ 5 ml Peroralna suspenzija Peroralna uporaba
1000/200 mg Powder for solution for injection or infusion
1000 mg/200 mg Powder for Solution for Injection or Infusion
Clavamox intravenös 550 mgTrockenstechampullen
Clavamox intravenös 550 mg
1000mg : 100mg/ vial
1000 mg : 100 mg/ vialo
Clavamel 125mg/31.25mg Paediatric Powder for Oral Suspension
125 mg/31,25 mg Paediatric Powder for Oral Suspension
Augmentin 1 g Tablets
Augmentin 1 gFilmtabletten
AND Powder and solvent for solution for injection
IN Prašek in vehikel za raztopino za injiciranje
Clavamox intravenös 2,2 gTrockensubstanz zur Infusionsbereitung
Clavamox intravenös 2,2 g - Trockensubstanz zur Infusionsbereitung
Augmentin intravenös 1,1 gTrockensubstanz zur Infusionsbereitung
Augmentin intravenös 1,1 g - Trockensubstanz zur Infusionsbereitung
2000mg : 200mg/ vial
2000 mg : 200 mg/ vialo
Augmentin intravenös 2,2 gTrockensubstanz zur Infusionsbereitung
Augmentin intravenös 2,2 g - Trockensubstanz zur Infusionsbereitung
Powder for injection
Prašek za raztopino za injiciranje
Clavamox intravenös 1,1 gTrockensubstanz zur Infusionsbereitung
Clavamox intravenös 1,1 g - Trockensubstanz zur Infusionsbereitung
Augmentin (80 /11.97 mg/ml) 400/57mg/ 5ml Powder for oral suspension
Augmentin (80 /11,97 mg/ml)
875mg/125mg Film Coated Tablets
Augmentin 875 mg/125 mg Film Coated Tablets
Augmentin 1 g - Filmtabletten 875/125 mg
Augmentin 1 g Tablets 875/125 mg
500mg : 100mg/ 10.5ml or 60 ml
500 mg : 100 mg/ 10,5 ml ali 60 ml
Augmentin 250/125mg
Augmentin 250/125 mg 250/125 mg
500mg / 50mg/ 10.5ml or 25ml
500 mg / 50 mg/ 10,5 ml ali 25 ml
250/62.5mg/ 5 ml
250/62,5 mg/ 5 ml (Amoxicillin:
Middlesex TW8 9GS UK
Middlesex TW8 9GS VB
Augmentin intravenös 550 mg - Trockenstechampullen
Augmentin intravenös 550 mg
Belgium GlaxoSmithKline s.a. / n.v. Rue du Tilleul 13
Belgija GlaxoSmithKline s.a. / n.v.
500mg : 50mg/ 10.5ml or 25ml
500 mg : 50 mg/ 10,5 ml ali 25 ml
125/31.25 mg/ 5 ml
125/31,25 mg/ 5 ml (Amoxicillin 25 mg/ml)
Powder for injection or infusion
Prašek za injiciranje ali infundiranje
Augmentin 156 mg/5 ml
Augmentin 312 mg/5 ml 250/62,5 mg/ 5 ml
Augmentin Intravenous 600mg 500/100 mg
Augmentine Intravenoso 500/50 mg
Augmentin 125/31 SF Sachet 125/31.25mg Powder for oral suspension
Augmentin 156 mg/5 ml 125/31,25 mg / 5 ml Prašek za peroralno suspenzijo
400/57mg/ 5ml (Amoxicillin: 80 mg/ml)
400/57 mg/ 5 ml (Amoxicillin:
Beecham Group plc 980 Great West Road, Brentford, Middlesex TW8 9GS
Romunija Beecham Group PLC 980 Great West Road, Brentford, Middlesex TW8 9GS
Augmentine Intravenoso
Intravenous
This summary was last updated: 19/11/2010
Povzetek je bil nazadnje posodobljen 19/11/2010.
These side effects occur generally within the first week of treatment and are usually temporary and disappear once treatment has stopped.
Ti neželeni učinki se običajno pojavijo v prvem tednu zdravljenja in so navadno prehodni ter po končanem zdravljenju minejo.
Other information about Meloxoral:
Druge informacije o zdravilu Meloxoral:
It can be used for both acute disorders, such as those seen after an injury, and chronic (long term) disorders.
Lahko se uporablja za akutna obolenja, do katerih pride ob poškodbi, in tudi za kronična (dolgotrajna) obolenja.
If the product is swallowed by a person, the advice of a doctor should be sought immediately.
Če oseba zaužije zdravilo, se je treba nemudoma posvetovati z zdravnikom.
Meloxoral contains the active substance meloxicam in a strength of 0.5 mg/ml (cats) or 1.5 mg/ml (dogs) for the oral suspension.
Zdravilo Meloxoral vsebuje zdravilno učinkovino meloksikam v jakosti 0,5 mg/ml (mačke) ali 1,5 mg/ml (psi) v peroralni suspenziji.
People who are hypersensitive (allergic) to NSAIDs should avoid contact with Meloxoral.
Osebe, ki so preobčutljive za (alergične na) nesteroidna protivnetna zdravila, naj se izogibajo stiku z zdravilom Meloxoral.
Studies looked at how Meloxoral was absorbed and its effects in the body, in comparison with Metacam.
V študijah so proučevali absorbiranje zdravila Meloxoral in njegove učinke na telo v primerjavi z zdravilom Metacam.
Meloxoral contains meloxicam, which belongs to a class of medicines called non-steroidal antiinflammatory drugs (NSAIDs).
Zdravilo Meloxoral vsebuje meloksikam, ki spada v skupino zdravil, imenovanih nesteroidna protivnetna zdravila (NSAID).
The Committee for Medicinal Products for Veterinary Use (CVMP) considered that, in accordance with European Union requirements, Meloxoral has been shown to be bioequivalent to Metacam.
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je menil, da se je zdravilo Meloxoral v skladu z zahtevami Evropske unije izkazalo biološko enakovredno zdravilu Metacam.
Meloxoral is a ‘generic' which means that Meloxoral is similar to a ‘reference veterinary medicine' already authorised in the EU (Metacam).
Zdravilo Meloxoral je generično zdravilo, kar pomeni, da je podobno referenčnemu veterinarskemu zdravilu, ki je že odobreno v EU (zdravilu Metacam).
The European Commission granted a marketing authorisation valid throughout the European Union, for Meloxoral to LeVet B.V. on 19/11/2010.
Evropska komisija je dovoljenje za promet z zdravilom Meloxoral, veljavno po vsej Evropski uniji, odobrila družbi LeVet B.V.
prostaglandins are substances that trigger inflammation, pain, exudation and fever, meloxicam reduces those responses.
Prostaglandini so snovi, ki povzročajo vnetje, bolečino, izločanje tekočine in zvišano telesno temperaturo, meloksikam pa zmanjšuje obseg teh odzivov.